Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast development

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    317 result(s) found for: Breast development. Displaying page 1 of 16.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-003992-35 Sponsor Protocol Number: MREC02/8/71 Start Date*: 2009-12-16
    Sponsor Name:Queen Mary University of London
    Full Title: International Breast Cancer Intervention Study II (DCIS). An international multi-centre trial of tamoxifen v anastrozole in post-menopausal women with ductal carcinoma in situ.
    Medical condition: Ductal carcinoma in situ
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10013806 Ductal carcinoma in situ LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012439-14 Sponsor Protocol Number: 155-CL-036 Start Date*: 2010-01-26
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer
    Medical condition: Adenocarcinoma of the breast that is HER2 negative.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed) BE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003932-32 Sponsor Protocol Number: ESTEeM 112984 U106/7672 Start Date*: 2006-12-14
    Sponsor Name:The University of Leeds [...]
    1. The University of Leeds
    2. The University of Sheffield
    Full Title: Endocrine +/- Surgical Therapy for Elderly women with Mammary cancer
    Medical condition: Women 75 years or over with invasive, operable, moderate or strongly ER+ve, primary breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006187 Breast cancer LLT
    Population Age: Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005186-31 Sponsor Protocol Number: 01062017 Start Date*: 2018-06-06
    Sponsor Name:Department of Plastic Surgery, Breast and Burns Treatment
    Full Title: Fat Grafting with Ex-Vivo Expanded Adipose-Derived Stem Cells for Breast Reconstruction Following Mastectomy
    Medical condition: This study will include patients with genetic predisposition to development of breast cancer, who are offered prophylactic bilateral skin-sparring mastectomy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10071981 BRCA2 gene mutation PT
    20.0 10018065 - General disorders and administration site conditions 10071980 BRCA1 gene mutation PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000436-27 Sponsor Protocol Number: BR3031 Start Date*: 2007-02-16
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. University Hospital Birmingham NHS Foundation Trust
    Full Title: Neoadjuvant trial of pre-operative exemestane or letrozole +/-celecoxib in the treatment of ER positive postmenopausal early breast cancer.
    Medical condition: Postmenopausal early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-002505-35 Sponsor Protocol Number: ABCSG_50 Start Date*: 2018-06-25
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline...
    Medical condition: Prevention of breast cancer in women with a BRCA1 germline mutation
    Disease: Version SOC Term Classification Code Term Level
    21.0 10042613 - Surgical and medical procedures 10036898 Prophylaxis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    23.0 10010331 - Congenital, familial and genetic disorders 10071980 BRCA1 gene mutation PT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002173-28 Sponsor Protocol Number: C4391002 Start Date*: 2023-01-25
    Sponsor Name:Pfizer Inc.
    Full Title: PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMB...
    Medical condition: HR-positive HER2-negative metastatic/advanced BC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018389-22 Sponsor Protocol Number: LAP113957 / SOLTI-1001 Start Date*: 2010-09-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, multicentre, open-label, Phase II study of the efficacy and safety of lapatinib plus epirubicin and cyclophosphamide (EC90-L) followed by weekly paclitaxel and lapatinib (PX-L) compar...
    Medical condition: patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) AT (Prematurely Ended) FR (Completed) NO (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021587-15 Sponsor Protocol Number: ICORG10-04NSABP-B46I Start Date*: 2010-09-08
    Sponsor Name:ICORG
    Full Title: A Phase III Clinical Trial Comparing TC to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
    Medical condition: Adjuvant Breast Cancer: Node positive or high risk node negative and HER 2 negative
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001839-21 Sponsor Protocol Number: LAP106988 / CHERLOB Start Date*: 2006-11-22
    Sponsor Name:GLAXO SMITH KLINE
    Full Title: CHEMOTHERAPY PLUS LAPATINIB OR TRASTUZUMAB OR BOTH IN HER2 PRIMARY BREAST CANCER. A RANDOMIZED PHASE IIb STUDY WITH BIOMARKER EVALUATION.
    Medical condition: MALIGNANT NEOPLASM FEMALE BREAST
    Disease: Version SOC Term Classification Code Term Level
    6.1 10057654 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001907-13 Sponsor Protocol Number: LAP107692 Start Date*: 2005-12-21
    Sponsor Name:GLAXO SMITH KLINE RESEARCH DEVELOPMENT LTD
    Full Title: LETROZOLE versus LETROZOLE PLUS LAPATINIB GW572016 IN HORMONE-SENSITIVE, HER-2 NEGATIVE OPERABLE BREAST CANCER. A DOUBLE BLIND RANDOMIZED PHASE II STUDY WITH BIOMARKER EVALUATION
    Medical condition: Primary breast cancer hormone-sensitive in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    6.1 10057654 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-002018-37 Sponsor Protocol Number: BO27938 Start Date*: 2013-04-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BRE...
    Medical condition: HER2-positive primary breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) IE (Prematurely Ended) ES (Ongoing) GR (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001467-20 Sponsor Protocol Number: COBC Start Date*: 2017-08-19
    Sponsor Name:Dept. of Oncology, Karolinska university hospital
    Full Title: Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long- Term Incidence of Clinical Cardiotoxicity in Women with Breast Cancer, a prospective randomised study: The Cardio-...
    Medical condition: Women with newly diagnosed breast cancer who are expected to receive neo-adjuvant or adjuvant therapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020806 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004532-58 Sponsor Protocol Number: LA-EP06-301 Start Date*: 2012-08-20
    Sponsor Name:Sandoz GmbH
    Full Title: A randomized, double-blind, parallel-group, multi-center Phase 3 comparative study investigating efficacy and safety of LA-EP2006 and Neulasta® in breast cancer patients treated with myelosuppressi...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006203 Breast cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-024481-22 Sponsor Protocol Number: EP06-302 Start Date*: 2012-01-17
    Sponsor Name:Sandoz GmbH
    Full Title: A randomized, double-blind, parallel-group, multi-center Phase III study comparing the efficacy and safety of EP2006 and Neupogen® in breast cancer patients treated with myelosuppressive chemothe...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006203 Breast cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2018-004648-44 Sponsor Protocol Number: MedOPP253 Start Date*: 2020-07-06
    Sponsor Name:Medica Scientia Innovation Research S.L (MEDSIR)
    Full Title: A multicentre, Open-Label, Non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in Combination with non-Taxane chemotherapy agents for taxane-pre...
    Medical condition: UNRESECTABLE LOCALLY ADVANCED OR METASTATIC RIPLE-NEGATIVE BREAST CANCER PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002667-53 Sponsor Protocol Number: 213409 Start Date*: 2021-08-23
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and are Judged by the Investigator to Benefit...
    Medical condition: advanced ovarian, breast, or prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) FR (Trial now transitioned) DK (Completed) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001952-16 Sponsor Protocol Number: PTW-1 Start Date*: 2021-01-07
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Progesterone for Breast Development in Trans Women; Assessment of effects and safety -a pilot trial-
    Medical condition: Hormone treatment of transgender women, we will investigate whether addition of progesterone to estradiol treatment results in an increase of breast volume and if there are side effects.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002155-17 Sponsor Protocol Number: LAP105594 Start Date*: 2008-04-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positiv...
    Medical condition: Advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumour cells
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006412-29 Sponsor Protocol Number: 3144A1-203-WW Start Date*: 2007-10-18
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: A Phase 1 / 2 Study of HKI-272 in combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
    Medical condition: Metastatic breast cancer remains incurable and represents an area of unmet medical need globally. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) activat...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 04:40:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA